Sunday, August 02, 2015 10:52:32 AM
1. This is a complicated subject. All of the following is based on my inadequately informed opinion.
2. There is no such thing as a "world patent". An inventor seeking international patent protection first applies an international patent application under the PCT system, indicating the "States" (generally meaning countries) in which it is seeking protection. That application acts as the basic document allowing the inventor to pursue a patent with the individual States. A Written Opinion of the International Search Authority gives the States a starting point in their own assessment of whether the invention is patentable.
3. The patent that you have linked is for SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS .....its status in the US is "Abandoned -- Failure to Respond to an Office Action" as was communicated to the company's attorneys on 3/4/14. So the link didn't "contain some or all of the info in question" and you might want to toss it...it has little value except to provide the history leading to its abandonment.
Start here:
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20100008938&OS=20100008938&RS=20100008938
and follow to here using application # 12/518,411:
http://portal.uspto.gov/pair/PublicPair
Click on "Image file wrapper".
4. None of the above addresses the question raised, the broad version of which was "Can we show that TheraCour owns the patents for which it is listed as "Owner" in the 10-K given that the patents listed do not show any assignment to TheraCour on any of the official websites that provide both international and domestic patent data?".
Specifically, under Owners, the first patent in the table says "TheraCour Pharma and Univ. of Massachusetts, Lowell", but USPTO.gov and https://patentscope.wipo.int/search/en/advancedSearch.jsf show the only assignee to be Univ. of Massachusetts, Lowell.
The second patent in the table shows TheraCour Pharma, Inc. as owner, but the US patent indicates that Allexcel, Inc. is the assignee.
The third patent in the table, which is the one that you linked, has as noted been abandoned in the US, so for US purposes it doesn't matter.
http://www.sec.gov/Archives/edgar/data/1379006/000114420414058463/v390044_10k.htm
p.61
I only looked at the US information....if any of the foreign applications or grants show different assignees I wouldn't know that and won't be looking to find out.
5. I believe the patent that you intended to link is entitled "SOLUBILIZATION AND TARGETED DELIVERY OF DRUGS WITH SELF-ASSEMBLING AMPHIPHILIC POLYMERS". (#2 in the Table)
http://www.sec.gov/Archives/edgar/data/1379006/000114420414058463/v390044_10k.htm
p.61
I appreciate your attempt to pitch in on this issue....I need all the help I can get. Feel free to try again, keeping in mind that the basic question, since we all have seen the license and amendments between TheraCour and NNVC, is "Where is it documented that TheraCour" OWNS the patent or patents underlying that license?".
“I have had a wonderful time but this wasn't it.”
..........Groucho
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM